Abstract
We examined the effects of cyclosporin A (CsA) and glucocorticoid (GC; hydrocortisone sodium succinate) in a mouse model of experimental parkisonism. GC or CsA was administered 30 or 60 min, respectively, prior to intracerebroventricular injection of 6-hydroxydopamine, followed by injection of a similar dose of each drug 3 h later. CsA reduced the extent of depletion of striatal concentrations of dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) associated with dopaminergic neuronal degeneration. GC reduced the extent of homovanillic acid (HVA) depletion in the same region. A combination treatment with CsA and GC did not produce a further enhancement of the recovery of striatal concentrations of monoamines observed with CsA only. Our findings demonstrated the beneficial effects of initial CsA treatment in experimental models of parkinsonism and further support the usefulness of CsA in the treatment of Parkinson's disease.
| Original language | English |
|---|---|
| Pages (from-to) | 191-194 |
| Number of pages | 4 |
| Journal | Neuroscience Letters |
| Volume | 230 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - Jul 25 1997 |
Fingerprint
Keywords
- 6-Hydroxydopamine
- Combination treatment
- Glucocorticoid
- Initial cyclosporin A treatment
- Monoamine concentration
- Parkinson's disease
ASJC Scopus subject areas
- Neuroscience(all)
Cite this
Initial cyclosporin A but not glucocorticoid treatment promotes recovery of striatal dopamine concentration in 6-hydroxydopamine lesioned mice. / Matsuura, Kouji; Kabuto, Hideaki; Makino, Hirofumi; Ogawa, Norio.
In: Neuroscience Letters, Vol. 230, No. 3, 25.07.1997, p. 191-194.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Initial cyclosporin A but not glucocorticoid treatment promotes recovery of striatal dopamine concentration in 6-hydroxydopamine lesioned mice
AU - Matsuura, Kouji
AU - Kabuto, Hideaki
AU - Makino, Hirofumi
AU - Ogawa, Norio
PY - 1997/7/25
Y1 - 1997/7/25
N2 - We examined the effects of cyclosporin A (CsA) and glucocorticoid (GC; hydrocortisone sodium succinate) in a mouse model of experimental parkisonism. GC or CsA was administered 30 or 60 min, respectively, prior to intracerebroventricular injection of 6-hydroxydopamine, followed by injection of a similar dose of each drug 3 h later. CsA reduced the extent of depletion of striatal concentrations of dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) associated with dopaminergic neuronal degeneration. GC reduced the extent of homovanillic acid (HVA) depletion in the same region. A combination treatment with CsA and GC did not produce a further enhancement of the recovery of striatal concentrations of monoamines observed with CsA only. Our findings demonstrated the beneficial effects of initial CsA treatment in experimental models of parkinsonism and further support the usefulness of CsA in the treatment of Parkinson's disease.
AB - We examined the effects of cyclosporin A (CsA) and glucocorticoid (GC; hydrocortisone sodium succinate) in a mouse model of experimental parkisonism. GC or CsA was administered 30 or 60 min, respectively, prior to intracerebroventricular injection of 6-hydroxydopamine, followed by injection of a similar dose of each drug 3 h later. CsA reduced the extent of depletion of striatal concentrations of dopamine (DA) and dihydroxyphenylacetic acid (DOPAC) associated with dopaminergic neuronal degeneration. GC reduced the extent of homovanillic acid (HVA) depletion in the same region. A combination treatment with CsA and GC did not produce a further enhancement of the recovery of striatal concentrations of monoamines observed with CsA only. Our findings demonstrated the beneficial effects of initial CsA treatment in experimental models of parkinsonism and further support the usefulness of CsA in the treatment of Parkinson's disease.
KW - 6-Hydroxydopamine
KW - Combination treatment
KW - Glucocorticoid
KW - Initial cyclosporin A treatment
KW - Monoamine concentration
KW - Parkinson's disease
UR - http://www.scopus.com/inward/record.url?scp=0030748668&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0030748668&partnerID=8YFLogxK
U2 - 10.1016/S0304-3940(97)00515-6
DO - 10.1016/S0304-3940(97)00515-6
M3 - Article
C2 - 9272693
AN - SCOPUS:0030748668
VL - 230
SP - 191
EP - 194
JO - Neuroscience Letters
JF - Neuroscience Letters
SN - 0304-3940
IS - 3
ER -